Comparative Pharmacology
Head-to-head clinical analysis: ERGOLOID MESYLATES versus HYDERGINE LC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERGOLOID MESYLATES versus HYDERGINE LC.
ERGOLOID MESYLATES vs HYDERGINE LC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.
Ergoloid mesylates (dihydroergotoxine) act as a partial agonist/antagonist at dopamine (D1, D2), serotonin (5-HT1, 5-HT2), and alpha-adrenergic receptors. They enhance cerebral metabolism and increase blood flow via vasodilation and neuroprotection.
Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.
Oral, 1 mg three times daily. Titrate up to 2 mg three times daily if needed.
None Documented
None Documented
2-4 hours for parent drug; clinical significance: drug accumulation unlikely with normal dosing intervals.
Terminal elimination half-life: 12–15 hours. Clinical context: steady-state achieved in 2–3 days; allows once-daily dosing.
Primarily fecal (biliary) as metabolites and unchanged drug; renal elimination accounts for less than 10% of the dose.
Renal (80% as metabolites, <1% unchanged); biliary/fecal (20%).
Category A/B
Category C
Ergot Alkaloid
Ergot Alkaloid